TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06389422

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Moderate-dose Hypofractionated Intensity-modulated Radiotherapy
Description: All lesions receive moderate-dose hypofractionated intensity-modulated radiotherapy, with a gross tumor dose of 25Gy/5f, and a maximum dose of 35Gy/5f at the tumor center.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: One week before or during the radiotherapy, patients receive concurrent Pembrolizumab at a dose of 200mg. Subsequently, Pembrolizumab is administered intravenously every 3 weeks. Follow-up examinations are conducted 1-3 months post-radiotherapy. Lenvatinib 4mg may be used for maintenance therapy with Pembrolizumab if there are no contraindications. Maintenance therapy is continued until disease progression or intolerance.
Study: NCT04220463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis + NIV
Description: For the hypnosis group, hypnotic support is set up by a doctor/IDE previously trained and dedicated during the implementation of the NIV. The dedicated doctor/IDE will be presented before the start of the NIV setup procedure and will start the hypnosis session a few minutes before the mask is put on. The procedure for setting up the NAV may begin after agreement from the dedicated doctor/IDE.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NIV
Description: In the control group, in order to preserve the knowledge of the evaluator, the doctor/IDE dedicated to hypnosis is present in the service but does not intervene in the care so as not to be tempted to involuntarily put hypnosis in place. The assessor will be chosen from the two other teams present in the other two modules (each module is a seven-bed unit and has no physical communication with the other two) after the start of the procedure for setting up the NIV, with or without hypnosis, in order to be certain that he had no visual contact with the patient and the caregivers present before the evaluation. The implementation of the NAV will take place as usually carried out in the service.
Study: NCT04984733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Metronomic TMZ 50mg/m2/day orally for 3 months then nivolumab 240mg IV +/- TMZ until progression.~Patients who don't progress on TMZ will commence with combination treatment; TMZ + Nivolumab at 3 mths. Patients who progress on TMZ will start monotherapy with nivolumab. Patients will remain on monotherapy with nivolumab or combination therapy until progression or up to a maximum of 24mths.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide 50mg/m2/day
Description: Metronomic TMZ 50mg/m2/day orally until progression then nivolumab 240mg IV until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide 3 month
Description: Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV and TMZ until progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide 24month
Description: Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV and TMZ until a maximum of 24 months
Study: NCT05208866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixivaptan
Description: Oral vasopressin V2 receptor antagonist
Study: NCT05864261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JT1801 60ug
Description: JT1801, 60ug, IV injection
Study: NCT06087653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Low-dose lenalidomide continuous SC infusion (STAR-LDD) in combination with bortezomib and dexamethasone
Study: NCT06070883

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Amniotic membrane transplantation
Description: Amniotic membrane (AM) is the innermost layer of the placenta, which consists of a single layer of meta-bolically active epithelium, a thick basement membrane, and an avascular stromal matrix. It has been shown to exhibit a wide array of biological properties, including wound healing, anti-inflammatory, antimicrobial, and anti-angiogenic properties, amongst others. Amniotic membrane transplantation will be performed in eye OT under aseptic conditions. The necrotic tissues at the base of the ulcer will be debrided and sent for culture and sensitivity. The rolledup edge of the ulcer or the loosely adhered epithelium adjacent to the ulcer will also be removed. The amniotic membrane will be trimmed to fit the shape of the ulcer and placed with its epithelial side up. Then the amniotic membrane will be secured with 10-0 nylon suture (5 cases with interrupted and 25 cases with continuous suture) with the suture knots buried.
Study: NCT06266247

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Take blood samples
Description: Tnf alpha, sirtuin and il-6 levels will be examined in patients with Behcet\&amp;#39;s disease using biological drugs and not using biological drugs
Study: NCT05468996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remimazolam
Description: A loading dose of remimazolam is 1mg/kg/hr. When sedation is achieved, the dose of remimazolam is adjusted to the assigned dose. The maintenance dose of remimazolam begins at 1.0mg/kg/hr. When the maintenance is not successful during the surgery, the maintenance dose will be increased by 0.1-0.2mg/kg/hr in the next patient. When the maintenance is successful, the dose will be decreased by 0.1-0.2mg/kg/hr. (maximal dose: 2mg/kg/hr)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remimazolam
Description: A loading dose of remimazolam is 1mg/kg/hr. When sedation is achieved, the dose of remimazolam is adjusted to the assigned dose. The maintenance dose of remimazolam begins at 1.0mg/kg/hr. When the maintenance is not successful during the surgery, the maintenance dose will be increased by 0.1-0.2mg/kg/hr in the next patient. When the maintenance is successful, the dose will be decreased by 0.1-0.2mg/kg/hr. (maximal dose: 2mg/kg/hr)
Study: NCT05864261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NESP 60ug
Description: NESP, 60ug, IV injection
Study: NCT05710861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F-HIFU
Description: A F-HIFU treatment will be performed with the Focal-One® machine according to the predefined treatment area for each patient using the standard procedure in place in each therapeutic center and according to the user's manual edited by the company, under locoregional or general anaesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Prostatectomy
Description: A Radical Prostatectomy will be performed according to the standard procedure in place in each center, under general anaesthesia, through an open, laparoscopic or robot-assisted laparoscopic approach
Study: NCT05402748

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placenta-MSCs derived exosomes
Description: Exosomes are extracellular vesicles that are 30 to 150 nm in diameter. these vesicles are secreted from various cells. Mesenchymal stem cells exhibit immunomodulatory and anti- inflammatory properties by the use of paracrine effects. Exosomes as a vehicle for signaling, are responsible for a major part of cell to cell signaling. The preclinical animal studies manifested high safety and efficacy for MSC derived exosome treatment on various fistulas and inflammatory bowel disease. In this study we aimed to evaluate the safety and efficacy of Placenta-MSCs derived exosomes in treatment of patients with complex preanal fistula (non-crohn's) in phase I and II of clinical trial.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placenta-MSCs derived exosomes
Description: Exosomes are extracellular vesicles that are 30 to 150 nm in diameter. these vesicles are secreted from various cells. Mesenchymal stem cells exhibit immunomodulatory and anti- inflammatory properties by the use of paracrine effects. Exosomes as a vehicle for signaling, are responsible for a major part of cell to cell signaling. The preclinical animal studies manifested high safety and efficacy for MSC derived exosome treatment on various fistulas and inflammatory bowel disease. In this study we aimed to evaluate the safety and efficacy of Placenta-MSCs derived exosomes in treatment of patients with complex preanal fistula (non-crohn's) in phase I and II of clinical trial.
Study: NCT05373589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional ventilation, group C
Description: In the conventional ventilation group, after stopping the administration of the inhalation gas, the emergence process is performed by the anesthesiologist assigned to the room. Basically, until spontaneous respiration of the patient is restored, an anesthesiologist can assist respiration by intermittent manual assistance if necessary.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pressure support, group PS
Description: In the pressure support group, after stopping the administration of the inhalation gas, switch to the pressure support mode at the emergence period. PEEP 5cmH20 is applied, and the safety backup ventilation rate is set to 12 breaths/min. The flow trigger is set to 1L/min, and the degree of support is made to be 7-8ml of the predicted body weight, and is decreased as the patient's spontaneous breathing is restored.
Study: NCT05065333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Septic Shock Clinical Decision Support
Description: The intervention will be activating a septic shock clinical decision support tool (CDS) in the Electronic Health Record at the site, making it available to trigger and alert Emergency Department providers during clinical care. Patients will be identified when providers suspect sepsis and initiate a sepsis evaluation, using the institutional, clinically-standard, sepsis pathway/orderset. After the CDS is triggered, it will use available Electronic Health Record data to calculate the risk of septic shock, using previously-published predictive models \[Ref 1, 2\]. The CDS will notify providers if the patient is at elevated risk of septic shock and prompt them to follow institutional standard care for septic shock (including close monitoring, complete laboratory evaluation for organ dysfunction, and immediate clinical involvement of an attending Pediatric Emergency Physician). All clinical care decisions will be determined by the providers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Diagnosis Only
Description: Emergency Department sites in this arm will not have Clinical Decision Support for septic shock visible in the Electronic Health Record for providers at the site. Providers will follow usual institutional standards of sepsis care.
Study: NCT06164509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alphintern® , tablet, Amoun, Egypt
Description: Medications will be taken three times daily for 7 days postoperative, after that all cases will be reexamined regarding healing rate, adverse effect and failure rate of medical treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alphintern® , tablet, Amoun, Egypt
Description: Medications will be taken three times daily for 7 days postoperative, after that all cases will be reexamined regarding healing rate, adverse effect and failure rate of medical treatment.
Study: NCT04908462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL01211 or Placebo (Part A)
Description: Five dose groups with doses ranging from 2mg to 60 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL01211 or Placebo (Part B)
Description: Five dose groups with doses ranging from 2-60 mg daily. Each separate dose given for 14 days
Study: NCT06266715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATP Group
Description: Cap escitalopram 10mg OD for four weeks and injection ATP 100mg in 100ml NS BD for two weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Cap escitalopram 10mg OD for four weeks and injection110ml NS BD for two weeks.
Study: NCT05468996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remimazolam
Description: A loading dose of remimazolam is 1mg/kg/hr. When sedation is achieved, the dose of remimazolam is adjusted to the assigned dose. The maintenance dose of remimazolam begins at 1.0mg/kg/hr. When the maintenance is not successful during the surgery, the maintenance dose will be increased by 0.1-0.2mg/kg/hr in the next patient. When the maintenance is successful, the dose will be decreased by 0.1-0.2mg/kg/hr. (maximal dose: 2mg/kg/hr)
Study: NCT05207488

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructooligosaccharides (FOS)
Description: FOS (NUTRAFLORA® P-95, Ingredion) supplements (10g/day) will be consumed daily mixed with water.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: During the intervention period, all participants will perform 6 weeks of supervised progressive multi-component exercise training consisting of moderate to vigorous aerobic and strength-based exercises (3x/wk.).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: During the intervention period, all participants will perform 6 weeks of supervised progressive multi-component exercise training consisting of moderate to vigorous aerobic and strength-based exercises (3x/wk.).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin (Globe 18DE Maltodextrin, Ingredion) supplements (10g/day) will be consumed daily mixed with water.
Study: NCT05907863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of intracardiac echocardiography
Description: intracardiac echocardiography guided slow pathway ablation in patients with AVNRT
Study: NCT05971667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil
Description: tadalafil 10 mg one tablet daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: sildenafil 20 mg two tablets daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxifylline
Description: pentoxifylline 400 mg two tabs daily
Study: NCT06276907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma Exchange
Description: On day 1 Response assessment will be done to assess the need for a second session from day 3-7 and subsequently every week till day 28. A minimum of 3 sessions would be considered in the first seven days. The duration of each session would be 3-4 hours. Patients with partial response (not meeting criteria for a complete response after 3 sessions) would be considered for additional sessions as decided by the treating physician until desired complete response, adverse effects, liver transplant, death, or clinical futility. The complete response will be defined as a sustained reduction in bilirubin and international normalized ratio without any clinical worsening requiring discontinuation of therapy. Failure of therapy would be defined as the development of adverse effects, new onset sepsis, or organ failure. In such patients, further sessions would be deferred. Blood access was established with a double-lumen catheter inserted into the patient's femoral or jugular vein.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Patients randomized to SMT Group will be given standard medical therapy (SMT) only included as per requirement.
Study: NCT04984746

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: No Intervention: (control group)
Description: Lettuce without any biofortification was assigned to each participant belonging to the control group which ate 100gr every day for 10 days
Study: NCT05540288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene
Description: Week 1: 18 mg/d~Week 2:~1. In the absence of ARs or in the presence of grade 1 or 2 ARs, 36 mg/d~2. In the presence of grade 3 ARs, 18 mg/d~3. In the presence of grade 4 ARs, treatment will be stopped immediately.~Week 3 to week 5:~1. In case of acceptable safety profile at the 18mg/d dosage during week 2, the treatment will be maintained at the same dosage~2. In the presence of sustained grade 3 ARs at the 18mg/d dosage during week 2, the treatment will be stopped.~3. In case of acceptable safety profile at the 36mg/d dosage during week 2, the treatment will be maintained at the same dosage~4. In the presence of grade 3 ARs at the 36mg/d dosage during week 2, the treatment dosage will be decreased at 18mg/d~5. Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Week 1: 1 tablet/d~Week 2:~1. In the absence of ARs or in the presence of grade 1 or 2 ARs, 2 tablets/d~2. In the presence of grade 3 ARs, 1 tablet/d~3. In the presence of grade 4 ARs, the treatment will be stopped immediately.~Week 3 to week 5:~1. In case of acceptable safety profile at the dosage of 1 tablet/d during week 2, the treatment will be maintained at the same dosage~2. In the presence of sustained grade 3 ARs at the dosage of 1 tablet/d during week 2, the treatment will be stopped.~3. In case of acceptable safety profile at the dosage of 2 tablets/d during week 2, the treatment will be maintained at the same dosage~4. In the presence of grade 3 ARs at the dosage of 2 tablets/d during week 2, the treatment dosage will be decreased at 1 tablet/d~5. Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately.
Study: NCT04984746

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: intervention group
Description: Molybdenum Iodine group~Lettuces with Iodine and Molybdenum biofortification was assigned to each participant belonging to the intervention group which ate 100gr of each type of lattuce every day for 10 days
Study: NCT05536336

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Condom
Description: Contraception

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Condom
Description: Contraception
Study: NCT05369741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TIME™ at Home
Description: Components of each 1.5-hour session:~1. Pre-class social time (15 min): Unstructured - introductions, safety, and technology troubleshoot, and social interactions if time allows~2. Exercise video (1 hour pre-recorded): a) 10-minute seated warm up; b) 40-minute functional exercises in standing, with standardized progressions and variations. Exercises are selected from the original, in-person TIME™ program and are deemed safe to perform at home by rehabilitation experts; and c) 10-minute seated cool down~3. Post-class social time (15 min): Structured and unstructured social interactions~4. Facilitators: A live virtual facilitator assisted by a co-facilitator to stream video, provide verbal encouragement and technology support~5. Healthcare partner e-visits: A registered healthcare professional will make 2-3 e-visits. They will observe the class and engage with participants during the post-class social time and debrief with facilitators.
Study: NCT04798196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ElderTree on laptop (ET- LT)
Description: ElderTree (ET) is an existing intervention providing tools, motivation, and support on a computer platform to help older adults manage their health.~ET is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support. ET-LT arm will access ET on Laptop (ET- LT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ElderTree on smart system (ET- SS)
Description: ElderTree (ET) is an existing intervention providing tools, motivation, and support on a computer platform to help older adults manage their health.~ET is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support.~ElderTree on smart system (ET- SS) will use voice-activated smart speakers connected to the Internet. Because they are used by talking and listening rather than typing and reading, many barriers associated with laptop use can be avoided.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Treatment as usual (TAU)
Study: NCT05692297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: The patients in the denosumab group received subcutaneous injection of denosumab 60mg once every 6 months for 24 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-denosumab
Description: Taken other medications, such as diphosphonates, active vitamin D and/or active vitamin D analogue, calcimimetics, calcitonin, estrogen receptor agonists, etc.
Study: NCT05882097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transform program
Description: International Care Ministries' (ICM) Transform is a 15-lesson, 15-week long values, health, and livelihood program that targets some of the poorest households in Uganda. The health dimension focuses on increasing health knowledge and behaviours on a range of health topics such as malnutrition, respiratory infection, lifestyle, sanitations, family planning and infant care. The livelihood dimension focuses on increasing the amount and sources of household income. Participants will learn about business ideas and farming techniques to diversify their income sources. Additionally, a savings group will be formed at the end of Transform to promote a sustainable strategy to reduce poverty among the participants. The values dimension will focus on relationships, personal character and decision making aspects of an individual.
Study: NCT06112561

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO/CI/SVR
Description: fluctuations of CO/CI/SVR regarding data from radial or femoral arterial cannula, and the therapeutic intervention that it demands these values.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO/CI/SVR
Description: fluctuations of CO/CI/SVR regarding data from radial or femoral arterial cannula, and the therapeutic intervention that it demands these values.
Study: NCT05511792

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAVR for BAV Using Down Sizing with the Evolut Pro platform
Description: Down sizing strategy in Type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement with self-expanding valves

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAVR for BAV Using Traditional Sizing strategy with the Evolut Pro platform
Description: Traditional sizing strategy in Type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement with self-expanding valves
Study: NCT04465760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xisomab 3G3
Description: Given IV or via catheter